WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 408095
Description: CADD522 is a potent inhibitor of runt-related transcription factor-2 (RUNX2)-DNA binding with an IC50 of 10 nM. CADD522 treatment resulted in significant growth inhibition, clonogenic survival, tumorsphere formation, and invasion of breast cancer cells. CADD522 negatively regulated transcription of RUNX2 target genes such as matrix metalloproteinase-13, vascular endothelial growth factor and glucose transporter-1, but upregulated RUNX2 expression by increasing RUNX2 stability. CADD522 reduced RUNX2-mediated increases in glucose uptake and decreased the level of CBF-β and RUNX2 phosphorylation at the S451 residue.
MedKoo Cat#: 408095
Chemical Formula: C15H13Cl2NO3
Exact Mass: 325.0272
Molecular Weight: 326.173
Elemental Analysis: C, 55.24; H, 4.02; Cl, 21.74; N, 4.29; O, 14.72
Synonym: CADD522; CADD-522; CADD 522
IUPAC/Chemical Name: 3-((3,4-dichlorophenyl)carbamoyl)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid
InChi Key: YSDNWNOGHQYWPK-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H13Cl2NO3/c16-10-4-3-9(6-11(10)17)18-14(19)12-7-1-2-8(5-7)13(12)15(20)21/h1-4,6-8,12-13H,5H2,(H,18,19)(H,20,21)
SMILES Code: ClC1=C(Cl)C=CC(NC(C2C(C3)C=CC3C2C(O)=O)=O)=C1
The RUNX2 transcription factor promotes breast cancer growth and metastasis through interactions with a variety of cofactors that activate or repress target genes.
1: Kim MS, Gernapudi R, Choi EY, Lapidus RG, Passaniti A. Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget. 2017;8(41):70916-70940. Published 2017 Aug 10. doi:10.18632/oncotarget.20200